Absence seizures in children and teenagers: ethosuximide, valproate or lamotrigine? A systematic review from 1999 to 2021 / Apreensões de ausência em crianças e adolescentes: etosuximida, valproato ou lamotrigina? Uma revisão sistemática de 1999 a 2021

Gustavo de Oliveira e Souza, Felipe Sarsur de Lanna Machado, Thais Yuki Kimura, Henrique Lacerda Lage Lopes de Oliveira


The onset of AS generally occurs during childhood or adolescence, and it is the most prevalent convulsion in 15 to 20% of epileptic children. Historically, first-line drugs in pediatric AS are Ethosuximide (ETX), Valproic Acid (VPA), and Lamotrigine (LTG). This review aims to determine the best pharmacological therapy for pediatric AS, considering that all three drugs have been established as superior to placebo.


“Absence seizures”, “Absence epilepsy”, “Ethosuximide”, “Valproic acid”, “Lamotrigine”, “Drug therapy”

Full Text:



Somerville, E. R. (2009). Some treatments cause seizure aggravation in idiopathic epilepsies (especially absence epilepsy). Epilepsia, 50 Suppl 8, 31–36. https://doi.org/10.1111/j.1528-1167.2009.02233.x

Posner, E. (2006). Pharmacological treatment of childhood absence epilepsy. Expert Review of Neurotherapeutics, 6(6), 855–862. https://doi.org/10.1586/14737175.6.6.855

Yasumoto, S., Ohtsuka, Y., Sato, K., Kurata, A., Numachi, Y., & Shimizu, M. (2018). Long-term efficacy and safety of lamotrigine monotherapy in Japanese and South Korean pediatric patients with newly diagnosed typical absence seizures: An open-label extension study. Brain & Development, 40(9), 786–791. https://doi.org/10.1016/j.braindev.2018.05.005

Huang, T.-S., Zhu, J.-L., Li, B., Hu, Y., Chen, L., & Liao, J.-X. (2009). [Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 11(8), 653–655.

Wheless, J. W., Clarke, D. F., Arzimanoglou, A., & Carpenter, D. (2007). Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disorders : International Epilepsy Journal with Videotape, 9(4), 353–412. https://doi.org/10.1684/epd.2007.0144

Posner, E. (2008). Absence seizures in children. BMJ Clinical Evidence, 2008.

Tsai, M.-F., & Chen, C.-Y. (2008). Valproate-induced hyperammonemic encephalopathy treated by hemodialysis. Renal Failure, 30(8), 822–824. https://doi.org/10.1080/08860220802272613

Williams, D. C. J., Massey, G. V, Russell, E. C., Riley, R. S., & Ben-Ezra, J. (2008). Translocation-positive acute myeloid leukemia associated with valproic acid therapy. Pediatric Blood & Cancer, 50(3), 641–643. https://doi.org/10.1002/pbc.21149

Rosati, A., Ilvento, L., Lucenteforte, E., Pugi, A., Crescioli, G., McGreevy, K. S., Virgili, G., Mugelli, A., De Masi, S., & Guerrini, R. (2018). Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta-analysis. Epilepsia, 59(2), 297–314. https://doi.org/10.1111/epi.13981

Jung, J., Eo, E., & Ahn, K. (2008). A case of hemoperfusion and L-carnitine management in valproic acid overdose. The American Journal of Emergency Medicine, 26(3), 388.e3-4. https://doi.org/10.1016/j.ajem.2007.07.032

Kanner, A. M., Ashman, E., Gloss, D., Harden, C., Bourgeois, B., Bautista, J. F., Abou-Khalil, B., Burakgazi-Dalkilic, E., Llanas Park, E., Stern, J., Hirtz, D., Nespeca, M., Gidal, B., Faught, E., & French, J. (2018). Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and t. Neurology, 91(2), 74–81. https://doi.org/10.1212/WNL.0000000000005755

Schmitt, B., Kovacevic-Preradovic, T., Critelli, H., & Molinari, L. (2007). Is ethosuximide a risk factor for generalised tonic-clonic seizures in absence epilepsy? Neuropediatrics, 38(2), 83–87. https://doi.org/10.1055/s-2007-984446

Tachibana, K., Hamada, T., Tsuchiya, H., Shibata, T., Fujii, K., Kobayashi, K., & Iwatsuki, K. (2018). Ethosuximide-induced Stevens-Johnson syndrome: Beneficial effect of early intervention with high-dose corticosteroid therapy. The Journal of Dermatology, 45(5), 592–595. https://doi.org/10.1111/1346-8138.14253

Yasumoto, S., Shimizu, M., Sato, K., Kurata, A., & Numachi, Y. (2016). Lamotrigine monotherapy for newly diagnosed typical absence seizures in children: A multi-center, uncontrolled, open-label study. Brain & Development, 38(4), 407–413. https://doi.org/10.1016/j.braindev.2015.10.007

Posner, E. B., Mohamed, K., & Marson, A. G. (2005). A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine. Seizure, 14(2), 117–122. https://doi.org/10.1016/j.seizure.2004.12.003

Lamotrigine and absence seizures: new indication. Try valproic acid first. (2009). Prescrire International, 18(104), 249.

Dunin-Wąsowicz, D., Mazurkiewicz-Bełdzińska, M., Steinborn, B., Wheless, J., & Jóźwiak, S. (2015). Treatment of pediatric epilepsy in Poland. European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society, 19(3), 320–326. https://doi.org/10.1016/j.ejpn.2014.12.023

Holmes, G. L., Frank, L. M., Sheth, R. D., Philbrook, B., Wooten, J. D., Vuong, A., Kerls, S., Hammer, A. E., & Messenheimer, J. (2008). Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. Epilepsy Research, 82(2–3), 124–132. https://doi.org/10.1016/j.eplepsyres.2008.07.016

Crespel, A., Velizarova, R., Agullo, M., & Gélisse, P. (2009). Ethosuximide-induced de novo systemic lupus erythematosus with anti-double-strand DNA antibodies: a case report with definite evidence. In Epilepsia (Vol. 50, Issue 8, p. 2003). https://doi.org/10.1111/j.1528-1167.2009.02144.x

Buechler, R. D., & Buchhalter, J. R. (2007). Juvenile absence epilepsy exacerbated by valproic acid. Pediatric Neurology, 36(2), 121–124. https://doi.org/10.1016/j.pediatrneurol.2006.08.011

Buoni, S., Grosso, S., & Fois, A. (1999). Lamotrigine in typical absence epilepsy. Brain & Development, 21(5), 303–306. https://doi.org/10.1016/s0387-7604(99)00023-6

Coppola, G., Auricchio, G., Federico, R., Carotenuto, M., & Pascotto, A. (2004). Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia, 45(9), 1049–1053. https://doi.org/10.1111/j.0013-9580.2004.40903.x

Das, K. B., Harris, C., Smyth, D. P. L., & Cross, J. H. (2003). Unusual side effects of lamotrigine therapy. Journal of Child Neurology, 18(7), 479–480. https://doi.org/10.1177/08830738030180070301

Echaniz-Laguna, A., Thiriaux, A., Ruolt-Olivesi, I., Marescaux, C., & Hirsch, E. (1999). Lupus anticoagulant induced by the combination of valproate and lamotrigine. Epilepsia, 40(11), 1661–1663. https://doi.org/10.1111/j.1528-1157.1999.tb02054.x

Frank, L. M., Enlow, T., Holmes, G. L., Manasco, P., Concannon, S., Chen, C., Womble, G., & Casale, E. J. (1999). Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia, 40(7), 973–979. https://doi.org/10.1111/j.1528-1157.1999.tb00805.x

Lerman-Sagie, T., Watemberg, N., Kramer, U., Shahar, E., & Lerman, P. (2001). Absence seizures aggravated by valproic acid. Epilepsia, 42(7), 941–943. https://doi.org/10.1046/j.1528-1157.2001.042007941.x

Posner, E. B., Mohamed, K., & Marson, A. G. (2003). Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. The Cochrane Database of Systematic Reviews, 3, CD003032. https://doi.org/10.1002/14651858.CD003032

Shahar, E., Andraus, J., Sagie-Lerman, T., & Savitzki, D. (2002). Valproic acid therapy inducing absence status evolving into generalized seizures. Pediatric Neurology, 26(5), 402–404. https://doi.org/10.1016/s0887-8994(01)00413-1

Wirrell, E., Camfield, C., Camfield, P., & Dooley, J. (2001). Prognostic significance of failure of the initial antiepileptic drug in children with absence epilepsy. Epilepsia, 42(6), 760–763. https://doi.org/10.1046/j.1528-1157.2001.02401.x

Cnaan, A., Shinnar, S., Arya, R., Adamson, P. C., Clark, P. O., Dlugos, D., Hirtz, D. G., Masur, D., & Glauser, T. A. (2017). Second monotherapy in childhood absence epilepsy. Neurology, 88(2), 182–190. https://doi.org/10.1212/WNL.0000000000003480

Kim, H. R., Kim, G. H., Eun, S. H., Eun, B. L., & Byeon, J. H. (2016). Therapeutic Outcomes and Prognostic Factors in Childhood Absence Epilepsy. Journal of Clinical Neurology (Seoul, Korea), 12(2), 160–165. https://doi.org/10.3988/jcn.2016.12.2.160

Ollivier, M. L., Dubois, M. F., Krajinovic, M., Cossette, P., & Carmant, L. (2009). Risk factors for valproic acid resistance in childhood absence epilepsy. Seizure, 18(10), 690–694. https://doi.org/10.1016/j.seizure.2009.09.007

Aldenkamp, A., Vigevano, F., Arzimanoglou, A., & Covanis, A. (2006). Role of valproate across the ages. Treatment of epilepsy in children. Acta Neurologica Scandinavica. Supplementum, 184, 1–13. https://doi.org/10.1111/j.1600-0404.2006.00666.x

Hanrahan, B., & Carson, R. P. (2021). Ethosuximide.

Rudrabhatla, P. K., Er, S., Radhakrishnan, A., Menon, R. N., Brigo, F., Igwe, S. C., Lattanzi, S., Mostacci, B., Ranzato, F., Giuliano, L., La Neve, A., Aguglia, U., Bilo, L., Durante, V., Ermio, C., Monti, G., Zambrelli, E., Lodi, M. A. M., Galimberti, C. A., … Marson, A. G. (2019). Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Epilepsia, 20(2), CD003032. https://doi.org/10.1007/s11940-014-0290-9

Gurbani, S., Chayasirisobhon, S., Gurbani, A., & McCall, N. (2020). Does Early Recognition of Treatment Failure and Changing Anti-Epilepsy Medication Regimen Improve Short-Term Seizure Remission Rates In Childhood Absence Epilepsy? Acta Neurologica Taiwanica, 29(2), 46–53.

Werbel, T., Castrovinci, P., & Contestable, J. (2019). Ethosuximide-induced drug reaction with eosinophilia and systemic symptoms with mediastinal lymphadenopathy. Pediatric Dermatology, 36(4), e99–e101. https://doi.org/10.1111/pde.13848

Cao, J., Lin, X.-X., Ma, X.-M., & Liu, H. (2020). The efficacy and safety of lamotrigine for absence seizures in children and adolescents: A systematic review and meta-analysis. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia, 71, 199–204. https://doi.org/10.1016/j.jocn.2019.08.043

Martínez-Ferrández, C., Martínez-Salcedo, E., Casas-Fernández, C., Alarcón-Martínez, H., Ibáñez-Micó, S., & Domingo-Jiménez, R. (2019). Long-term prognosis of childhood absence epilepsy. Neurologia (Barcelona, Spain), 34(4), 224–228. https://doi.org/10.1016/j.nrl.2016.12.005

Brigo, F., Igwe, S. C., & Lattanzi, S. (2021). Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. The Cochrane Database of Systematic Reviews, 1(1), CD003032. https://doi.org/10.1002/14651858.CD003032.pub5

Luijtelaar, G. van, Zobeiri, M., Lüttjohann, A., & Depaulis, A. (2017). Experimental Treatment Options in Absence Epilepsy. Current Pharmaceutical Design, 23(37), 5577–5592. https://doi.org/10.2174/1381612823666171017170226

Kessler, S. K., & McGinnis, E. (2019). A Practical Guide to Treatment of Childhood Absence Epilepsy. Paediatric Drugs, 21(1), 15–24. https://doi.org/10.1007/s40272-019-00325-x

Morse, E., Giblin, K., Chung, M. H., Dohle, C., Berg, A. T., & Blumenfeld, H. (2019). Historical trend toward improved long-term outcome in childhood absence epilepsy. Epilepsy Research, 152, 7–10. https://doi.org/10.1016/j.eplepsyres.2019.02.013

Albuja AC, Murphy PB. Absence Seizure. 2020 Nov 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 29763042.

IJff DM, van Veenendaal TM, Debeij-van Hall MH, Jansen JF, de Louw AJ, Majoie MH, Aldenkamp AP. The Cognitive Profile of Ethosuximide in Children. Paediatr Drugs. 2016 Oct;18(5):379-85. doi: 10.1007/s40272-016-0187-z. PMID: 27557905.

Tenney JR, Jain SV. Absence Epilepsy: Older vs Newer AEDs. Curr Treat Options Neurol. 2014 May;16(5):290. doi: 10.1007/s11940-014-0290-9. PMID: 24668022.

Masur D, Shinnar S, Cnaan A, Shinnar RC, Clark P, Wang J, Weiss EF, Hirtz DG, Glauser TA; Childhood Absence Epilepsy Study Group. Pretreatment cognitive deficits and treatment effects on attention in childhood absence epilepsy. Neurology. 2013 Oct 29;81(18):1572-80. doi: 10.1212/WNL.0b013e3182a9f3ca. Epub 2013 Oct 2. PMID: 24089388; PMCID: PMC3806916.

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Adamson PC; Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013 Jan;54(1):141-55. doi: 10.1111/epi.12028. Epub 2012 Nov 21. PMID: 23167925; PMCID: PMC3538883.

Hwang H, Kim H, Kim SH, Kim SH, Lim BC, Chae JH, Choi JE, Kim KJ, Hwang YS. Long-term effectiveness of ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. Brain Dev. 2012 May;34(5):344-8. doi: 10.1016/j.braindev.2011.08.007. Epub 2011 Sep 3. PMID: 21893390.

Zaki, E. L., & Springate, J. E. (2002). Renal injury from valproic acid: case report and literature review. Pediatric Neurology, 27(4), 318–319. doi:10.1016/s0887-8994(02)00447-2

DOI: https://doi.org/10.34119/bjhrv5n1-019


  • There are currently no refbacks.